Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 85%
filed 2026-08-07
Item 1.01
Capital Southwest Corporation entered into an equity distribution agreement with RBC Capital Markets on August 7, 2026, adding RBC as a sales agent to its existing at-the-market (ATM) offering program. The company may issue and sell up to $2.0 billion in aggregate common stock through the program, with approximately $1.1 billion remaining available as of the filing date. This is a registered dilutive equity issuance that would materially affect shareholder interests and the total mix of information available to investors.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-07
Item 3.02
QVC Group issued approximately 50 million shares of new common stock on the Plan Effective Date (August 6, 2026) pursuant to its Chapter 11 emergence, with 21.4 million shares issued to QVC Notes claimholders and 28.6 million shares to RCF claimholders, exempt from registration under Section 1145 of the Bankruptcy Code.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
The company issued approximately 50 million shares of New Common Stock to creditors (QVC Notes Claimholders and RCF Claimholders) pursuant to the bankruptcy reorganization plan, representing a substantial unregistered equity issuance exempt under Section 1145 of the Bankruptcy Code and Section 4(a)(2) of the Securities Act.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
Brookfield Private Equity Fund LP sold unregistered limited partnership units (Class S and Class I) for approximately $16.96 million on July 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions. This private placement represents part of a continuous offering that has raised approximately $358.5 million since November 2025.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-07
Item 1.01
Celestica entered into an underwriting agreement on August 5, 2026 to issue and sell 9,677,419 common shares at $310.00 per share, with underwriters exercising a full over-allotment option for an additional 1,451,612 shares. The offering generated approximately $3.39 billion in net proceeds. This is a material registered public offering of equity securities that dilutes existing shareholders and represents a significant capital-raising event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-07
EX-99.1
This exhibit is a PRC legal opinion issued in connection with the offering and sale of 150,000 American depositary shares (representing 4.5 million Class A ordinary shares) pursuant to a securities purchase agreement dated August 6, 2026. The opinion supports a registered direct offering under Form F-3, which is a dilutive equity issuance. The exhibit explicitly references "the offering and sale by the Company of 150,000 American depositary shares" and the associated transaction documents, confirming this is a material equity capital raise.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-07
Item 8.01
Summit Hotel Properties entered into an at-the-market (ATM) equity distribution agreement on August 7, 2026, authorizing the sale of up to $200 million in common stock through multiple sales agents. The filing explicitly describes sales "deemed to be 'at-the-market offerings' as defined in Rule 415 under the Securities Act," and includes forward sale arrangements where Forward Purchasers will borrow and sell shares to hedge their exposure. This is a classic dilutive equity issuance that would materially affect existing shareholders through potential dilution and is a significant capital-raising event for the REIT.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Rubico Inc. entered into an ATM (At-The-Market) Sales Agreement on August 5, 2026, authorizing the issuance and sale of up to $25 million of common shares through B. Riley Securities. An ATM offering is a dilutive equity issuance that allows the company to raise capital by selling shares at market prices over time, which is a material capital-raising event that would affect investor assessment of ownership dilution and the company's financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-07
Item 8.01
NNN REIT entered into an equity distribution agreement authorizing the issuance and sale of up to 25,000,000 shares of common stock through multiple sales agents and forward purchasers. This is a classic at-the-market (ATM) offering structure with forward sale agreements, which represents a dilutive issuance of equity securities. The magnitude (25 million shares) and the forward sale mechanics (including contingent and non-contingent forward transactions) are material to existing shareholders' interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-07
Item 3.02
The filing discloses a prospectus supplement covering resale of 1,958,951 shares of common stock by certain selling stockholders under a Form S-3ASR registration statement. While technically a resale by existing shareholders rather than a primary issuance by the company, the disclosure of registered resale capacity for a material number of shares signals potential dilution and is material to investors assessing capital structure and share count. The Item 3.02 classification and reference to the registration statement confirm this is equity-related disclosure, though the resale-versus-primary distinction introduces some ambiguity about whether this is purely dilutive in the traditional sense.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
The Company issued 2,615,087 common shares for approximately $52.4 million in gross proceeds on August 3, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
Fortress Net Lease REIT issued 8.6 million common shares for approximately $91.3 million in gross proceeds on August 3, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
The filing discloses multiple unregistered private placements of equity securities to accredited investors and directors under Section 4(a)(2) and Regulation D Rule 506(c), totaling approximately $3.65 million in aggregate proceeds across Class A-I, Class A-II, and Class E common stock issued on July 10 and August 3, 2026. This is a classic dilutive issuance of unregistered equity securities by a small-cap REIT raising capital through private placements, which materially affects shareholder ownership and is a key indicator of capital-raising activity.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
Goldman Sachs Real Estate Finance Trust Inc completed an unregistered private offering of Class I and Class S common stock totaling approximately $6.3 million in aggregate consideration to accredited investors under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
Interactive Strength issued 798,719 shares of Common Stock through a series of exchange agreements with preferred stockholders and note holders between August 3–7, 2026, relying on Section 3(a)(9) exemption from registration. This is a material unregistered equity issuance that increases share count from approximately 581,677 to 1,380,396 shares outstanding—a 137% dilution—and would materially affect a reasonable investor's assessment of ownership and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
The filing discloses an unregistered sale of 1,060,552.7919 common shares for $26.771 million in aggregate consideration under Section 4(a)(2) and Regulation D Rule 506. This is a classic private placement of equity securities exempt from registration, which is material to investors as it represents dilution and capital raising activity. The Item 3.02 designation and detailed breakdown of share classes and consideration confirm this is a dilutive equity issuance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 1.01
Red Violet completed a registered public offering of 1,916,667 shares of common stock (including full exercise of the underwriters' 15% option) at $60 per share on August 7, 2026, raising approximately $108.6 million in net proceeds. The offering was underwritten and registered on Form S-3, with proceeds intended for working capital, general corporate purposes, and potential strategic acquisitions.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-07
Item 1.01
The filing discloses a secondary offering of 20,000,000 shares of Class A Common Stock by a major stockholder (One Rock Capital Partners affiliate) that closed on August 7, 2026, generating $487.4 million in gross proceeds. While technically a secondary offering (shares sold by an existing stockholder rather than a primary issuance by the company), the substantial volume and market impact qualify this as a material capital event. The company also entered into a concurrent stock repurchase agreement to buy back 410,340 shares at the offering price, which is a related capital transaction. This disclosure under Item 1.01 (Material Definitive Agreement) reflects the company's involvement in the underwriting agreement and the repurchase agreement, making it a material event affecting share structure and investor interests.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 45%
filed 2026-08-07
EX-99.1
The announcement describes a 16-for-1 reverse split of ADSs (from 1 ADS per 375 shares to 1 ADS per 6,000 shares), effective August 27, 2026. While reverse splits are typically capital-structure adjustments rather than dilutive issuances, the repeated ADS ratio changes (this is the second in three months) and the context of a foreign private issuer with a Nasdaq listing suggest potential financial distress or stock-price support measures. However, the exhibit does not disclose new equity issuance, private placement, or convertible securities—it is purely a mechanical ADS consolidation. The classification is uncertain because reverse splits do not fit neatly into the taxonomy; they are neither a discrete event nor a periodic report, and the materiality depends on whether the market interprets this as a distress signal.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-08-07
Item 8.01
T1 Energy issued 13,615,979 shares of common stock to Evervolt as consideration for an intellectual property purchase on July 28, 2026. Although the prospectus supplement filed on August 7, 2026 covers resale by the holder (not a direct new issuance by the Company), the underlying event is a material unregistered equity issuance that dilutes existing shareholders. The shares were issued as acquisition consideration and are now registered for resale, creating significant dilution and liquidity risk typical of dilutive issuances disclosed under Item 3.02 or Item 8.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-07
Item 1.01
Alto Ingredients entered into an At-The-Market (ATM) Issuance Sales Agreement on August 5, 2026, authorizing the sale of up to $50.0 million in common shares. ATM offerings are a form of dilutive equity issuance that allows the company to raise capital opportunistically. The filing explicitly discloses the agreement with designated agents and the prospectus supplement filed under Rule 424(b), which are hallmarks of a registered equity offering. This is material to investors as it signals potential dilution and the company's capital-raising needs.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
iSpecimen Inc. entered into a placement agency agreement and securities purchase agreement on August 5, 2026, to issue and sell 996,231 shares of common stock and pre-funded warrants to purchase 2,849,923 additional shares for $5 million in aggregate proceeds. The offering closed on August 7, 2026, pursuant to a Form S-1 registration statement. This is a registered public offering of equity securities that is materially dilutive to existing shareholders and represents a significant capital raise for the company.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 92%
filed 2026-08-07
The Company entered into a Securities Purchase Agreement on August 7, 2026, establishing a $36 million commitment to fund pre-paid purchases over two years, with settlement through issuance of Class A Shares at 50% of market price (with a $0.10 floor). This is a dilutive equity issuance mechanism—a structured PIPE-like arrangement where the investor funds cash and the Company settles by issuing shares at a significant discount, creating substantial dilution to existing shareholders. The filing explicitly references a concurrent prospectus supplement for the offer and sale of Class A Shares.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
The 6-K discloses completion of a registered direct offering in which Nano-X sold 8,000,000 ordinary shares (or pre-funded warrants) and 8,000,000 ordinary warrants to a single institutional investor for approximately $8.0 million gross proceeds. This is a dilutive equity issuance under a registered shelf offering (Form F-3), meeting the definition of dilutive_issuance. The transaction is material as it represents a significant capital raise and equity dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-07
Item 3.02
The Company issued 537,335 shares of common stock in exchange for 1,252 shares of Series B Preferred Stock valued at $1,252,000. The issuance was unregistered and conducted under Section 3(a)(9) of the Securities Act. This represents a material dilutive equity issuance that would affect shareholder ownership and voting power, typical of the dilutive_issuance category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
The Company issued 779,371 shares of common stock to Lind Global Asset Management XII LLC in three tranches (July 14, July 16, and August 6, 2026) to satisfy payment and conversion obligations under senior secured convertible promissory notes. The issuance was made in reliance on Section 3(a)(9), Section 4(a)(2), and Rule 506 of Regulation D—all exemptions from registration that signal a private placement to an existing securityholder. This is a classic dilutive equity issuance that would materially affect a reasonable investor's assessment of share ownership and capital structure.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
The 6-K discloses a Securities Purchase Agreement dated August 7, 2026, under which Fusion Fuel Green PLC agreed to issue 431,367 Class A ordinary shares, pre-funded warrants, and common warrants for approximately $1,550,000 in gross proceeds. This is a classic private placement (PIPE) transaction conducted under Section 4(a)(2) and Regulation D Rule 506(b), involving unregistered equity issuance with warrant coverage that creates substantial dilution to existing shareholders. The company must register the resale securities on Form F-3 within 90 days and maintain effectiveness, with penalties for non-compliance.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
EX-99.1
The exhibit discloses completion of an underwritten public offering of 1,715,000 common shares at US$4.00 per share for aggregate gross proceeds of US$6.9 million, including participation by strategic investor Uranium Energy Corp. through its subsidiary. This is a material dilutive equity issuance that increases the share count and raises capital, with Uranium Energy's participation increasing its ownership from approximately 32.2% to 32.6% on a non-diluted basis.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Diginex disclosed a private placement of 20 million ordinary shares and 20 million warrants for $20 million, signed on July 20, 2026 with three unrelated investors. The offering was conducted under Section 4(a)(2) and Regulation D/S exemptions. This is a material dilutive equity issuance that raises capital and significantly increases share count, affecting existing shareholders' ownership percentages and earnings per share.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
On August 3, 2026, Ares Real Estate Income Trust Inc. completed an unregistered private placement under Regulation D, issuing 1,168,737 Class S-PR shares ($9.68M) and 1,727,341 Class I-PR shares ($14.20M) for gross proceeds of approximately $23.9M.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-07
EX-99.1
The press release announces a registered direct offering of 1,428,572 Class A ordinary shares and pre-funded warrants for $5.0 million gross proceeds at $3.50 per share. This is a dilutive equity issuance registered under Form F-3, representing new equity capital raised through the sale of registered securities to an institutional investor, which materially affects shareholder ownership and is a key financing event for the company.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-07
Item 3.02
The filing discloses an unregistered sale of equity securities totaling approximately $33.7 million across four classes of common stock on August 3, 2026, exempt from registration under Section 4(a)(2). This is a classic dilutive issuance event, particularly material given the aggregate consideration and the inclusion of shares issued to the investment adviser (Invesco Advisers, Inc.) as payment for management fees, which would affect existing shareholders' ownership percentages and voting power.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 8.01
Scholar Rock filed a prospectus supplement on August 6, 2026 to offer and sell up to $200 million in additional shares of common stock through an at-the-market (ATM) offering program. This is a registered equity issuance that will dilute existing shareholders and represents a material capital-raising event. The company has already raised approximately $257.7 million under the ATM Program, and this new prospectus supplement authorizes an additional $200 million in offerings.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 8.01
The filing discloses the underwriters' exercise of an option to purchase an additional 2,250,000 shares of common stock in a registered public offering, generating approximately $312.2 million in net proceeds. This represents a dilutive equity issuance that increases shares outstanding and would materially affect a reasonable investor's assessment of ownership dilution and capital structure, even though it is a registered offering rather than a private placement.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 1.01
Clearway Energy entered into an Equity Distribution Agreement (ATM Program) with major investment banks to offer and sell up to $100 million of Class C common stock at market prices. This at-the-market offering is a dilutive equity issuance to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Clearway Energy, Inc. entered into an Equity Distribution Agreement (ATM Program) on August 6, 2026, authorizing the sale of up to $100 million in Class C common stock through multiple investment banks. This is a classic at-the-market (ATM) offering—an unregistered or registered equity issuance program that creates potential dilution to existing shareholders. The filing explicitly references the prospectus supplement and shelf registration statement (Form S-3), confirming this is a registered direct offering of equity securities. Such capital-raising activities are material to investors assessing the company's financing strategy and shareholder dilution risk.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Aclaris entered into a Second Amended and Restated Sales Agreement (ATM Agreement) with Leerink and Cantor permitting the company to offer and sell shares of common stock "from time to time at the Company's sole discretion" through an at-the-market offering mechanism. This is a dilutive equity issuance arrangement that allows the company to raise capital by selling common stock to the public, which is material to investors as it signals potential capital needs and shareholder dilution.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 1.01
Innodata entered into an equity distribution agreement with multiple sales agents to offer and sell up to $300 million in common stock shares through an "at the market offering" under a newly filed Form S-3 shelf registration. This is a dilutive equity issuance that creates potential for substantial shareholder dilution and capital raising, which materially affects investor assessment of the company's capital structure and financing strategy.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 88%
filed 2026-08-06
Item 1.01
LTC Properties terminated its prior at-the-market equity distribution agreement and entered into a new Equity Distribution Agreement on August 6, 2026, permitting the issuance and sale of up to $500 million of common stock through sales agents and forward sale agreements. The company intends to use proceeds to pay down debt, fund acquisitions, and support working capital.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 1.01
Grace Therapeutics entered into a securities purchase agreement on August 4, 2026, to issue 4,761,904 shares of common stock at $2.10 per share in a private placement offering, generating approximately $10 million in gross proceeds. The unregistered securities were sold under Section 4(a)(2) of the Securities Act and Rule 506, with 90-day lock-up restrictions, representing a material dilutive issuance to raise capital for the company's operations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 80%
filed 2026-08-06
Item 1.01
Korro entered into an exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026, whereby Venrock surrendered 1,000,000 shares for no consideration and received pre-funded warrants to purchase 1,000,000 shares at $0.001 exercise price with no expiration date. The pre-funded warrants are immediately exercisable and represent a material dilutive issuance of equity securities that increases the company's outstanding share count.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 8.01
CG Oncology filed Amendment No. 2 to its prospectus on August 6, 2026, increasing the shares available for sale under an Open Market Sale Agreement (ATM offering) with Jefferies LLC by an additional $500 million, following prior $550 million in sales.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The filing discloses unregistered sales of equity securities totaling approximately $25.1 million across multiple tranches (June 1, July 1, and August 3, 2026) to accredited investors under Section 4(a)(2) and Regulation D exemptions. These private placements of common shares of beneficial interest represent dilutive equity issuances material to the fund's capital structure and investor base.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
The filing discloses an unregistered sale of 767,565 common shares for approximately $15.98 million under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive equity issuance in a continuous private offering, material to investors as it increases share count and dilutes existing shareholders' ownership interests.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Relay Therapeutics amended its at-the-market (ATM) offering agreement with TD Securities on August 6, 2026, increasing the authorized offering size from $250 million to approximately $463 million, allowing the company to sell an additional $213 million in shares through an unregistered equity program.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-08-06
Apple Hospitality REIT amended its equity distribution agreement on August 6, 2026, to continue selling up to $500 million of common shares through multiple agents. While the amendment itself is primarily administrative (updating agent definitions), the underlying equity distribution program represents a material dilutive issuance arrangement that allows the company to raise capital through at-the-market or negotiated offerings. This is material to investors as it signals the company's capital-raising strategy and potential dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-06
Item 3.02
TCGX Acquisition Corp. completed an unregistered private placement of 522,500 Class A ordinary shares at $10.00 per share ($5.225 million aggregate) to the Sponsor and Jefferies LLC, executed simultaneously with the IPO closing pursuant to Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 1.01
Organogenesis entered into an At-the-Market (ATM) Sales Agreement on August 6, 2026, authorizing the sale of up to $75 million in Class A common stock through agents BTIG and Citizens JMP Securities. ATM offerings are unregistered equity issuances that create dilution risk for existing shareholders and are a common capital-raising mechanism at small- and mid-cap issuers. The material amount ($75M) and the explicit authorization to sell shares "from time to time" through registered agents make this a dilutive issuance event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-06
Item 8.01
The Company filed a prospectus supplement on August 6, 2026 to offer and sell up to $200.0 million of common stock pursuant to an Amended and Restated Sales Agreement with Jefferies LLC. This represents a material dilutive equity issuance under an ATM (at-the-market) offering program, with the Company having already issued $85.0 million in shares under the prior prospectus supplement. The filing of a new prospectus supplement to increase the offering capacity signals a significant capital raise that would materially dilute existing shareholders.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-06
EX-99.1
This press release announces a registered direct offering of 8 million ordinary shares and 8 million warrants at $1.00 per unit, raising approximately $8 million gross proceeds. The offering is a registered direct placement under the company's Form F-3 shelf registration, representing a dilutive equity issuance to a single institutional investor. The warrant component (exercisable at $1.15, expiring five years from closing) adds further dilution potential. This is a material capital-raising event for a medical imaging company with acknowledged going-concern risks mentioned in the forward-looking statements.
View raw filing on EDGAR →